US › Healthcare

Nuvectis Pharma Inc (NVCT)

US · Healthcare · Biotechnology

$20.10-6.94%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-6.0M

Profit YoY

-13.5%

EPS

$-0.26

EPS estimate

$-0.31

EPS came in at -0.26 against a street estimate of -0.31 — a beat of 16.1%.

Key statistics

Market cap

$678.4M

Forward P/E

0.0

P/B

47.71

Book value

$0.54

EPS (TTM)

$-1.31

52-week high

$29.27

52-week low

$5.55

50-day MA

$16.18

200-day MA

$10.04

Beta

-0.25

Analyst view

Analysts rate Nuvectis Pharma Inc a buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $31.80.

Shareholding

Insiders

35.49%

Institutions

14.90%

Largest institutional holders

Fund	Stake
BlackRock Inc	2.42%
Vanguard Capital Management, LLC	2.09%
Iridian Asset Management LLC	2.07%
Occam Crest Management L.P.	1.29%
Geode Capital Management, LLC	1.22%
Baldwin Brothers Inc	1.21%
State Street Corp	0.53%
Northern Trust Corp	0.39%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Nuvectis Pharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.